Could A Type 1 Diabetes Immunotherapy Be In Reach?
Promising data from the likes of Provention Bio and Diamyd Medical suggest that treatment for the autoimmune disorder type 1 diabetes could soon move beyond insulin.
You may also be interested in...
Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.
Targeting CD3 to treat type 1 diabetes has once again been called into question as GSK and Tolerx revealed that the Phase III DEFEND-1 study of otelixzimuab did not meet its primary endpoint in patients with new-onset autoimmune type 1 diabetes. The partners have suspended new recruitment and dosing in the DEFEND-2 study pending review of the DEFEND-1 results. Last autumn, MacroGenics and partner Eli Lilly announced that their anti-CD3 mAb failed to show efficacy in a pivotal Phase II/III trial in type 1 diabetes patients missing the same primary endpoint.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.